AAIC

Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024

Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.

Key Points: 
  • Alector and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including AD and Parkinson’s disease.
  • In September 2023, Alector completed enrollment of 381 participants in the randomized, double-blind, placebo-controlled, dose-ranging, INVOKE-2 Phase 2 clinical trial.
  • In July 2023, Alector presented an update on INVOKE-2 at the Alzheimer’s Association International Conference (AAIC).
  • Alector’s management team will host a conference call discussing Alector’s results for the fourth quarter and full year 2023 and provide a business update.

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Retrieved on: 
Thursday, February 15, 2024

In addition, the Company provided 2024 financial guidance and business highlights.

Key Points: 
  • In addition, the Company provided 2024 financial guidance and business highlights.
  • “2023 was a year of strong progress for Prothena as we advanced our protein dysregulation portfolio and moved closer to becoming a fully integrated commercial company.
  • Total revenue for the fourth quarter and full year of 2023 included BMS collaboration revenue of $0.3 million and $91.3 million, respectively.
  • As of December 31, 2023, Prothena had $621.0 million in cash, cash equivalents and restricted cash, and no debt.

Income Tax Treatment of 2023 Distributions of Arlington Asset Investment Corp. Announced

Retrieved on: 
Thursday, February 1, 2024

Ellington Financial Inc. (NYSE: EFC) (the "Company"), as successor to Arlington Asset Investment Corp. (“AAIC”)1, today announced that information regarding the federal income tax treatment of the distributions deemed paid in 2023 on AAIC’s preferred stock, and the Form 8937 relating to the merger of AAIC into a subsidiary of the Company, have been posted to the Company’s website at the following links.

Key Points: 
  • Ellington Financial Inc. (NYSE: EFC) (the "Company"), as successor to Arlington Asset Investment Corp. (“AAIC”)1, today announced that information regarding the federal income tax treatment of the distributions deemed paid in 2023 on AAIC’s preferred stock, and the Form 8937 relating to the merger of AAIC into a subsidiary of the Company, have been posted to the Company’s website at the following links.
  • Common Stock: During the 2023 tax year, AAIC did not make any distributions to its common stock.

ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights

Retrieved on: 
Tuesday, November 14, 2023

CAMBRIDGE, Massachusetts, Nov. 14, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Key Points: 
  • “The third quarter was marked by significant progress across both our clinical and corporate initiatives,” said Gail Farfel, Ph.D., Chief Executive Officer of ProMIS Neurosciences.
  • These results replicated biomarker findings from the CLARITY-AD trial of lecanemab, which also predominantly targets soluble amyloid beta oligomers.
  • In July 2023, the Company presented preclinical data from mouse vaccination studies at AAIC 2023.
  • Net loss was $2.4 million for the quarter ended September 30, 2023, compared to a net loss of $6.0 million for the same period in 2022.

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, November 9, 2023

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.
  • R&D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30, 2022.
  • G&A expenses were $7.8 million for the quarter ended September 30, 2023, compared with $7.2 million for the quarter ended September 30, 2022.
  • The increase was primarily due to increases in personnel expenses, partially offset by a decrease in business development expenses.

LifeQ Partners with AAIC Investment to Improve Health Care in Africa and Lead Health Tech Revolution

Retrieved on: 
Monday, November 20, 2023

ATLANTA, Nov. 20, 2023 /PRNewswire/ -- LifeQ, the company that uses globally recognized watch brands to generate personalized, clinical-grade health insights, announced its partnership with AAIC Investment, a Singapore-based investment firm focusing on fast-growing companies within the healthcare sector in Africa. LifeQ co-founder Laurence (Laurie) Olivier, CEO, made the announcement.

Key Points: 
  • "LifeQ is proud to partner with AAIC Investment, who are deeply committed to improving healthcare in Africa and catalyzing value transfer between all their stakeholders," stated Mr. Olivier.
  • LifeQ's accessible, real-world healthcare solutions through wearable devices will have a significant positive impact for both consumer and clinical applications across Africa and beyond."
  • Established in 2013, AAIC Investment is the fund management arm of AAIC Holdings.
  • AAIC had already commenced connecting LifeQ with their Japanese stakeholders before their investment was finalized.

Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, November 8, 2023

With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.

Key Points: 
  • With planned enrollment completed and the DSMB endorsement, Annovis expects topline results at the end of January 2024.
  • Financial Results (for the quarter ending September 30, 2023)
    Cash and cash equivalents were $6.4 million.
  • Maria Maccecchini, Ph.D, Annovis founder, president, and CEO, has been named a 2023 Woman of Influence by the Philadelphia Business Journal.
  • The crystalline form of buntanetap will allow us to have a new 20-year patent protection for Annovis Bio to continue to move forward.

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Retrieved on: 
Friday, November 3, 2023

Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.

Key Points: 
  • Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “As we look to year-end and into 2024, AC Immune is poised to achieve multiple milestones across our clinical programs.
  • We remain on track to report safety and immunogenicity data from the AD cohort of our ABATE trial of ACI-24.060 this year.
  • Then, in the first half of 2024 results are anticipated from the important Abeta-PET imaging analyses on amyloid plaque reduction following 6 months of treatment.
  • The Company’s cash balance provides sufficient capital resources to progress into Q4 2024 without considering receipt of potential future milestone payments.

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

ARLINGTON ASSET INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Arlington Asset Investment Corp. - AAIC

Retrieved on: 
Friday, November 3, 2023

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arlington Asset Investment Corp. (NYSE: AAIC) to Ellington Financial Inc. (NYSE: EFC).

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Arlington Asset Investment Corp. (NYSE: AAIC) to Ellington Financial Inc. (NYSE: EFC).
  • Under the terms of the proposed transaction, shareholders of Arlington will receive 0.3619 shares of Ellington common stock and $0.09 in cash for each share of Arlington that they own.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .